A large phase 3 trial of Leronlimab in severe Covid 19 patients
Latest Information Update: 07 Apr 2022
At a glance
- Drugs Leronlimab (Primary)
- Indications COVID 2019 infections
- Focus Registrational; Therapeutic Use
- 30 Mar 2022 According to an CytoDyn media release, Company elected to pause its Brazil COVID-19 trials pending results from its previously scheduled data safety monitoring committee meeting.
- 30 Mar 2022 Status changed from recruiting to suspended, according to an CytoDyn media release.
- 25 Oct 2021 According to a CytoDyn media release, first patient has been treated in this trial.